Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men?

Autor: Roland Chapurlat, Cyrille B. Confavreux, Romain Casey, Joëlle Goudable, Pawel Szulc, Annie Varennes
Přispěvatelé: Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)
Jazyk: angličtina
Rok vydání: 2016
Předmět:
0301 basic medicine
Genetic Markers
Male
medicine.medical_specialty
Bone density
Endocrinology
Diabetes and Metabolism
[SDV]Life Sciences [q-bio]
Osteocalcin
030209 endocrinology & metabolism
Caucasian men
Cohort Studies
03 medical and health sciences
chemistry.chemical_compound
Bone Morphogenetic Proteins/*blood/physiology
0302 clinical medicine
Bone Density
Diabetes mellitus
Internal medicine
medicine
Humans
Sclerostin
Metabolic Syndrome/*blood
Adaptor Proteins
Signal Transducing
Aged
Metabolic Syndrome
biology
business.industry
Odds ratio
Middle Aged
medicine.disease
Confidence interval
Genetic Markers/physiology
030104 developmental biology
Endocrinology
Osteocalcin/*blood/physiology
Quartile
chemistry
Bone Morphogenetic Proteins
biology.protein
France
Metabolic syndrome
business
Bone mineral content
Zdroj: Osteoporosis International
Osteoporosis International, Springer Verlag, 2016, 27 (7), pp.2301-2309. ⟨10.1007/s00198-016-3540-8⟩
ISSN: 0937-941X
1433-2965
DOI: 10.1007/s00198-016-3540-8⟩
Popis: International audience; UNLABELLED: The reported association between sclerostin and diabetes mellitus or abdominal fat may be biased by body size and bone mass. In older men, the association between serum sclerostin levels and metabolic syndrome lost significance after adjustment for bone mass. The association between sclerostin and energy metabolism needs further clarification. INTRODUCTION: Sclerostin is associated with abdominal fat, but this relationship may be biased since both are associated with body size and bone mass. Osteocalcin is a bone-derived hormone regulating energy metabolism. We assessed the association between serum sclerostin and metabolic syndrome (MetS) accounting for whole body mineral content (BMC) and osteocalcin. METHODS: We studied 694 men aged 51-85 who had serum osteocalcin and sclerostin measurements. RESULTS: Sclerostin was higher in 216 men with MetS compared with those without MetS (p \textless 0.005). Average sclerostin level increased significantly across the increasing number of MetS components. In multivariable models, higher sclerostin was associated with higher odds of MetS (odds ratio (OR) = 1.24/1 standard deviation (SD) increase [95 % confidence interval (95 % CI), 1.01-1.51]; p \textless 0.05). After further adjustment for BMC, the association of MetS with sclerostin lost significance, whereas that with osteocalcin remained significant. Men who were simultaneously in the highest sclerostin quartile and the lowest osteocalcin quartile had higher odds of MetS (OR = 2.14 [95 % CI, 1.15-4.18]; p \textless 0.05) vs. men being in the three lower sclerostin quartiles and three upper osteocalcin quartiles. After adjustment for whole body BMC, the association lost significance. CONCLUSIONS: Higher sclerostin level is associated with MetS severity; however, this association may be related to higher whole body BMC. The adjustment for BMC had no impact on the association between MetS and osteocalcin. Clinical cross-sectional studies do not elucidate the potential role of sclerostin in the regulation of energy metabolism and direct experimental approach is necessary.
Databáze: OpenAIRE
Externí odkaz: